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Abstract
Background: The immunoprecipitation (IP) assay is a valuable molecular biology tool applied across a breadth of
fields. The standard assay couples IP to immunoblotting (IP/IB), a procedure severely limited as it is not easily scaled
for high-throughput analysis.
Results: Here we describe and characterize a new methodology for fast and reliable evaluation
of an immunoprecipitation reaction. FLIP (FLuorescence IP) relies on the expression of the target protein as a
chromophore-tagged protein and couples IP with the measurement of fluorescent signal coating agarose
beads. We show here that FLIP displays similar sensitivity to the standard IP/IB procedure but is amenable to
high-throughput analysis. We applied FLIP to the screening of mouse monoclonal antibodies of unknown behavior in
IP procedures. The parallel analysis of the considered antibodies using FLIP and IP/western shows good correlation
between the two procedures. We also show application of FLIP using unpurified antibodies (hybridoma supernatant)
and we developed a publicly available tool for the easy analysis and quantification of FLIP signals.
Conclusions: Altogether, our characterizations of this new methodology show that FLIP is an appealing and reliable
tool for any application of high-throughput IP.
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Background
In the post-Human Genome Project era, increasing and
growing interest is devoted towards proteomic ap-
proaches aimed at gaining new insight into the complex
ways cells interpret and regulate genomic information.
Consortia such as the Encyclopedia of DNA Elements
consortium and the Human Proteome Organization
(HPP) aim to fill the gap between the genomic and the
proteomic world [1, 2]. Mass spectrometry and antibody
capture analyses are the basic experimental strategies
used towards this goal. An essential tool for the study of
the function and interaction of proteins is the immuno-
purification of the protein of interest with or without its
interacting partners and molecules [3, 4].
The immunoprecipitation assay (IP) is an important tool
used in academic and industrial research labs for ap-
plications such as targeted protein purification, protein
concentration, analysis of protein-protein interactions,
identification/analysis of protein complexes and analysis
of protein/DNA interactions using chromatin IP (ChIP).
IP and ChIP are both inexpensive and highly informative,
relying on a specific antibody to selectively bind to the
target epitope with high affinity [5]. By combining this
binding reaction with a high molecular weight entity such
as a bead, a bacterial cell or a meshwork of secondary
antibodies, it is possible to isolate the protein of interest
and its binding partner(s) from all the other cellular
components in a microfuge tube [6]. However, not all
antibodies are well-suited for IP. For instance, for some IP
applications the antibody should recognize the target pro-
tein in its three-dimensional folded state, which requires
that the epitope be exposed on an accessible surface of the
target protein [7]. Therefore, there is a demand for high-
throughput assays to screen antibodies capable of IP of
target proteins [8, 9]. Moreover, because of the wide range
of applications of the IP assay, quick and high-throughput
ways to determine the success of an IP are necessary. Until
now the standard procedure to validate antibodies for IP
couples the IP assay to immunoblotting (IP/IB), a proced-
ure that is challenging to scale to high-throughput analysis
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[10]. Novel approaches for antibody validation combine
immunoprecipitation with mass spectrometry analysis
(IP/MS) but, despite the quantitative, highly sensitive and
informative nature of this approach, IP/MS is still a more
expensive and labor- and instrument-intensive procedure
compared to the more accessible IP/IB [6, 11]. Moreover,
success of IP/MS is highly dependent on both the cell type
and the abundance of the protein of interest.
To our knowledge the only high-throughput assay
developed for IP screening is LUMIER (luminescence-
based mammalian interactome mapping) system [12, 13].
LUMIER relies on the quantification of the luminescence
signal produced by the immunoprecipitation or co-
immunoprecipitation of an over-expressed target protein
tagged with Renilla luciferase. LUMIER was successfully
applied to a range of applications but, to our knowledge,
is still the only high-throughput option to classical IP/WB.
We have developed a novel assay for immunoprecipi-
tation, termed FLuorescence IP (FLIP) that is quick, reli-
able, easy to perform and scalable because it does not
rely on immunoblotting analysis. Additionally, due to
the small amount of material required, the FLIP assay
can be included in a standard IP/IB procedure without
affecting the output of the analysis. Because of these fea-
tures, the FLIP assay is ideal for high-throughput screen-
ing to identify IP-grade antibodies. Here we describe the
FLIP concept and apply it to the high-throughput identi-
fication of IP-proficient mouse monoclonal antibodies.
Methods
HuEV-A Cloning and Cre Recombination Reaction
The HuEV-A vector was constructed from a one-step
ligation reaction with two inserts and a vector fragment.
The backbone for the HuEV-A vector was the previously
described pCEP4-Puro plasmid [14]. The first insert was
a DNA fragment containing the chloramphenicol resist-
ance gene, ccdB gene and att-R2 site, and was con-
structed by joining a NotI/KpnI segment of the Gateway
Reading frame A cloning vector (Life Technologies, Cat
#11828-029) containing the chloramphenicol resistance
gene and the att-R2 site to a second synthetic DNA frag-
ment (UEV) containing the complementary att-R1 site
along with a series of epitope tags, recombination sites
and the Venus YFP sequence with BsiWI (compatible
with BsrGI) and EagI (compatible with NotI) termini.
The pCEP Puro backbone vector was digested with KpnI
and BsrGI and the inserts were ligated into the backbone
using T4 DNA ligase in ligase buffer (Enzymatics,
Beverly, MA; Prod. No L6030-HC). Vectors were
transformed into E. coli and selected on ampicillin/
chloramphenicol plates. The HuEV-A vector has been
deposited at Addgene (plasmid number 68342).
Cre recombination reactions were performed to gener-
ate HuEV-A expression plasmids lacking YFP in the tag.
One unit of Cre recombinase (New England Biolabs,
M0298), 0.25 μg of HuEV-A plasmid with intact tag, was
incubated in 50 μl of 1X Cre buffer (New England
Biolabs, Beverley, MA) at 37 °C for 30 min. Cre recom-
binase was then inactivated for 10 min at 70 °C and the
DNA purified on column (Qiagen, 28106). The eluted
DNA was then cut with PmlI enzyme for 1 h at 37 °C in
CutSmart buffer (New England Biolabs) to cut the not
recombined plasmids. PmlI has a unique site in the se-
quence between the LoxP sites. DNA was again column
purified, transformed in ccdB resistant competent cells
(Invitrogen, Carlsbad, CA; Prod. No A10460) and plated
on ampicillin selection plates. Colonies were screened by
colony PCR and the chosen clones verified by sequencing.
Cell Culture and Transient Transfection
HeLa-M2 cells were cultured in DMEM supplemented
with 10 % FBS (Gemini, Prod. No 100–106) and
1 mM L-glutamine (ThermoFisher/Life Technologies,
Prod. No 25030–081) [15]. Cells were routinely split in
fresh medium and new plates upon reaching 80–90 %
confluence. During routine culture of the cells the
medium was changed every 2–3 days.
The day before transfection 0.3 × 106 cells were plated
in each well of a 6-well plate (Falcon). The day after
plating, transfection was performed using Fugene-HD
reagent according to the manufacturer’s instructions
(Promega, Madison, WI; Prod. No E2311). For each well,
0.75 μg of DNA, 3 μl Fugene-HD and 50 μl of Opti-
MEM (Life Technologies, Prod. No 31985–070) were
incubated 15 min at room temperature. The transfection
mixture was then dripped into each well containing 2 ml
of complete media and the HeLa M2 cells plated the
previous day. Transfection conditions (number of cells
plated, DNA amount and Fugene-HD amount) used
in Fig. 4 are reported in Additional file 1: Figure S4.
We found that high transfection efficiency (>80 %)
depended on (i) confluency of cells prior to plating
(cell density >80 % confluence was detrimental); (ii) dur-
ation of incubation of plated cells prior to introduction of
foreign DNA/Fugene (incubation after plating of >18 h
was required); (iii) time after transfection before doxycyc-
line treatments (doxycycline treatments immediately after
transfection induced much lower expression compared to
doxycycline treatments started 18–24 h after transfection);
and purity/quality of DNA (all plasmids were prepared by
Maxi or Midipreps [Invitrogen PureLink, plasmid filter
kits, product number K210015]).
For the experiments presented here, doxycycline was
added to the medium immediately after transfection at a
final concentration of 1 μg/ml, which limited protein
expression from the HuEV-A vector but shortened the
timeline to cell harvest by a day. The expression of the
desired protein under the indicated conditions was
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sufficient to guarantee a reliable FLIP and/or an IP/IB
analysis in 96 % of the cases. Sporadic low expression
was attributed to inaccurate cloning of the target protein
into the expression vector.
Cell Lysis and Conventional Immunoprecipitation
For the parallel analysis of mouse antibodies (CDI Labora-
tories) using FLIP and IP/IB assays in a 96 well IP format
(Fig. 5), an entire 6-well plate was used for each target
protein. Cells were treated with 0 (one well), 50 ng/ml
(2 wells) or 1 μg/ml (3 wells) doxycycline and lysates ob-
tained from one well were used for one IP. After 24 h of
doxycycline treatment, cells were lysed in Triton lysis buf-
fer (20 mM HEPES, 1 % Triton X-100, 500 mM NaCl)
supplemented at the time of use with protease inhibitor
tablets (Roche, Prod. No 11697498001). 150 μl of lysis buf-
fer were used to lyse the cells cultured in one well, and
120 μl of clarified cell lysate were used for each IP/ FLIP.
IPs were performed with a normal mouse IgG Abs (Sigma,
Prod. No sc-2025) as a negative control (using lysates
from cells treated with 1 μg/ml doxycycline); FLAG-M2
antibody (Sigma, Prod. No F1804) as positive control
(using lysates from cells treated with 1 μg/ml doxycycline);
or the test antibody (using lysates from cells treated with
50 ng/ml and 1 μg/ml doxycycline). After SDS-PAGE and
transfer of the proteins onto a PVDF-F membrane, pro-
teins were probed with a rabbit polyclonal antibody
against FLAG tag (Cell Signaling #2368) mixed with the
test mouse antibody. Secondary goat antibodies conju-
gated to IRDye680 (anti-rabbit) or IRDye800 (anti-mouse)
dyes (LiCOR), were used for the detection of the recog-
nized bands on an Odyssey CLx scanner (LiCOR). The
efficiency with which the tested mouse Ab was able to
immunoprecipitate the over-expressed target protein was
calculated by quantifying the intensity of the band of the
protein immunoprecipitated with the tested mAb over the
intensity of the band of the protein from the total lysate
lane (IP INPUT) (Additional file 1: Figure S5). Correcting
for the different volumes/amount loaded on the gel, the %
of target protein immunoprecipitated (% tot. lysate) was
calculated. FLIP was performed on the beads from FLAG
IP, IgG IP and tested mAb IP and using only cell lysates
from cells treated with 1 μg/ml doxycycline.
For the experiments described in Fig. 3, HeLa cells
were plated and transfected in multiple 3-cm wells as
described above, and all wells were treated with 1 μg/ml
doxycycline for 24 h starting from the day after transfec-
tion. Cells were lysed in Triton buffer supplemented
with protease inhibitors, and FLIP was performed as de-
scribed below in 1.5 ml tubes (low throughput FLIP).
For the IP performed with hybridoma supernatant
(Fig. 7), lysates from cells expressing UPF1 protein from
the HuEV-A vector were used. Lysates from about two
3-cm wells were used to IP the tagged UPF1 protein
using 200 μl (≈1:3 dilution) of hybridoma supernatant, (of
unknown antibody concentration), or control mouse IgG
antibodies (5 μg). The IP was conducted in 0.7 ml of total
volume in 1.5 ml tubes using protein A/G beads [16, 17].
A Mini-FLIP assay (described below) used to evaluate
the same hybridoma supernatants was performed using
40 μl (1:3 dilution) of hybridoma supernatant in a total
volume of 120 μl.
FLIP
Before performing FLIP assays, the YFP content of ly-
sates from cells expressing the YFP-tagged protein of
interest was measured to determine the amount of YFP
present in each μl of lysate. The fluorescence of 10 μl of
lysate was measured in clear-bottom black 384-well
plates and compared to a standard curve obtained
measuring the fluorescence of known amounts of re-
combinant YFP (MBL International Corporation; Prod.
No JM-4998-100) (a typical standard curve ranged from
0 to 500 ng of recombinant YFP). If an autogain was set
for the fluorescence reading, the samples and the stand-
ard curve dilutions were always read on the same plate.
In this study, an excitation wavelength of 475 nm, and
emission wavelength of 527 nm, were used for YFP de-
tection using a Synergy H1 reader (BioTek). After quan-
tifying the amount of YFP, an estimate of FLIP efficiency
was determined from the curve in Fig. 3a. Considering
that the curve in Fig. 3a was obtained using a well-
behaved FLAG antibody, 700 μl of lysate containing at
least 0.5 ng/μl of YFP (at least 350 ng of total YFP per
IP) should be used for each FLIP to ensure a reliable
measurement and quantification of fluorescence from
the beads using FLIP performed in 1.5 ml tubes (large
volume FLIP). Our characterizations showed that the
sensitivity of the FLIP increased with an increase of
YFP-protein in the lysate used for the assay. To ensure
reliable FLIP results, especially for antibodies with weak
affinity, the use of more than 350 ng of YFP-protein in
the initial lysate is recommended.
A much lower amount of YFP and lysate is needed for
mini-FLIP assays, in which 100–120 μl of lysate contain-
ing at least 0.3 ng/μl of YFP-protein can be used.
We have observed the YFP fluorescence on the beads
to be highly stable in our FLIP assays. YFP signal coating
the agarose beads was still observed up to one week after
IP, with a negligible decrease in FLIP sensitivity, when
the plate containing the FLIP beads was stored in the
dark at 4 °C.
Large Volume FLIP
Lysates from cells expressing the YFP-protein of interest
were aliquoted into 1.5 ml tubes (700 μl per tube). 5 μg
of tested or control IgG antibodies was added directly
into the lysates and incubated for 1 h at 4 °C on a
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nutating mixer (Fisher Scientific) to ensure continuous
agitation of the sample. 50 μl of Protein A/G agarose
beads (Santa Cruz, Prod. No sc-2003) slurry was then
added to each tube and incubated for 30 min at 4 °C on
a roller. Beads were washed 5 times in Triton buffer
(800 μl of buffer per wash). During the last wash, 10 μl
of beads/buffer solution were transferred into black 384
well plates for analysis with a microscope, while the re-
mainder of the beads were collected and processed for
immunoblotting analysis. For the latter analysis, the im-
mune complexes were eluted from the beads by adding 1X
NuPage LDS sample buffer (Life Technologies, Prod. No
NP0007) supplemented with 350 mM β-mercaptoethanol.
Samples were heated at 75 °C for 10 min and stored
at −20 °C until immunoblotting analysis.
High Throughput (HiT) FLIP
For the parallel analysis of mouse monoclonal antibodies
using FLIP and IP/IB assays presented in Fig. 5, a
96-well format was used for IP/FLIP. 700 μl of lysates
prepared as described above were aliquoted to each well
of a 96-deep-well plate (Nunc). The 96-well format
allowed for manipulation of the samples using multichan-
nel pipettes. Each YFP-protein expressed in HeLa cells
was treated with 0, 50 or 1000 ng/ml doxycycline as
described above. 5 μg of antibodies was added to the ap-
propriate wells containing the target YFP-protein of inter-
est. Every antibody required 4 wells for analysis: mouse
IgG control Ab was added to a well containing lysates of
cells treated with 1000 ng/ml doxycycline; anti FLAG-M2
Ab was added to a well containing lysates of cells treated
with 1000 ng/ml doxycycline; mAb to be tested was added
to a well containing lysates of cells treated with 1000 ng/ml
doxycycline and to a well containing lysates of cells treated
with 50 ng/ml doxycycline. The plate was sealed with
aluminum sealing tape and incubated 1 h at 4 °C on a
nutator to ensure continuous agitation of the sample. 50 μl
of Protein A/G agarose bead slurry were added to each well
and incubated for 30 min at 4 °C on a nutator. Beads were
then washed 5 times with Triton buffer without disturbing
the bead pellet when removing the supernatant. Approxi-
mately 50–100 μl of Triton buffer was left in each well dur-
ing washes, and long loading tips (Fisher) were used to
discard the washes to minimize bead loss. Multichannel tip
adaptors attached to a vacuum pump were used for quick
handling of the samples during washes. After the last wash
(with 800 μl), 10 μl of beads from the mouse IgG IP and
from the IP with the tested Ab was collected from each
well and transferred to a 384 well plate. These samples
were then analyzed for FLIP while the rest of the beads
were processed for immunoblotting analysis. The left-over
beads were collected by centrifugation and the last wash
was discarded using loading tips. The bead pellet can be
quickly touched to get rid of most of the buffer before
eluting the immuno-complexes into 1X NuPage LDS sam-
ple buffer supplemented with 350 nM β-mercaptoethanol.
The plate was then heated to 75 °C for 10 min and the
sample buffer containing the immune complexes that
were eluted from the beads was transferred to 96-well
PCR plates, sealed and stored at −20 °C until im-
munoblotting analysis.
Mini-FLIP
Lysates from cells expressing the YFP-protein of interest
were aliquoted into PCR tubes (100–120 μl per tube).
FLIP was then conducted using the large volume FLIP
procedure as described above, except 10 μl of protein
A/G slurry per tube and 100 μl of Triton buffer for each
wash was used. 10 μl of beads was collected during the
last wash, and the fluorescence coating the beads was
analyzed with a fluorescence microscope.
Image Analysis
After IP, a distinct and sharp fluorescent ring around the
edges of the beads was indicative of a positive FLIP,
whereas a uniform, unfocused fluorescence on the bead
was indicative of background signal. A simple examin-
ation of the collected pictures by eye is sufficient for
qualitative determination of FLIP results, and discrimin-
ation of FLIP-positive from FLIP-negative antibodies.
In this report, FLIP analysis was performed using
pictures of YFP-coated beads analyzed with ImageJ
(Micro-manager 1.4.18, University of California). For a
simple quantification of the total mean fluorescence per-
formed using ImageJ, it was important that the beads
were allowed to settle and form a uniform layer on the
bottom of the plate, and that a comparable number of
beads were analyzed for different IPs from the same
lysate. A low but comparable number of beads was pref-
erable over an excess of beads distributed in different
layers in the well. An EVOS FL auto (Life technologies)
or a BD-pathway microscope (BD bioscience) was used
to automatically collect images of the YFP coating the
beads after IP, but any fluorescence microscope with an
appropriate filter should be suitable for the acquisition
of FLIP images. 384-well black plates with clear bottoms
were used and pictures were taken with a 20X magnifi-
cation, keeping the microscope parameters (exposure
time, contrast and gain) constant for all the pictures
taken for the same experiment. All the pictures were
then opened with ImageJ software and the brightness/
contrast set at equal values for all the pictures of the
same experiment. The total mean fluorescence of the
pictures was then measured and the value obtained from
the corresponding IgG control IP subtracted from the
mean fluorescence obtained from the IP using the tested
mAb (or FLAG Ab) ([mean fluorescence from IP using
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FLAG antibodies] – [mean fluorescence from IP using
IgG control antibodies]).
Software for FLIP Image Analysis
The FLIP image analysis software was developed in
Python utilizing the Sci-Kit Image analysis package and
a multitude of other supporting packages. The function
of the software is to isolate and quantify the image signal
from two regions of interest, the prominent bright ring
at the perimeter of the agarose bead, and the body of the
bead itself. Once the features are isolated, the average
intensities of the respective regions are calculated and the
FLIP signal is returned as the difference between the
signals for the two regions. The true FLIP signal for the
real-IP image was then calculated by subtracting the FLIP
signal for its corresponding IgG control. Before using this
software it is recommended that a uniform distribution of
beads in the sample be visually confirmed in advance. A
free and publicly available analysis tool for FLIP pictures
can be found at http://openslice.fenyolab.org/flip.
Results
FLIP Assay Using HuEV-A Expression Vector
Immunoprecipitation assays take advantage of the bind-
ing in solution of an antibody to a specific target pep-
tide, protein or protein complex. Beads conjugated to
protein A (for rabbit antibodies), protein G (for mouse
antibodies) or to protein A and G (A/G), or to certain
bacterial cells displaying these proteins on their surface,
will bind the Ab-target complex, allowing the highly
specific isolation of the target protein from a complex
solution. The specificity is ensured by the highly select-
ive interaction of the Ab to the target protein of interest.
Washes of beads coated with the Ab-target complex
ensure the clean purification/concentration/isolation of
the target protein of interest. In standard IP/IB assays
(immunoprecipitation followed by immunoblotting ana-
lysis) the target protein or complex of interest is eluted
from the beads and subsequently visualized and analyzed
by SDS-PAGE (SDS polyacrylamide gel electrophoresis)
followed by immunoblotting. In contrast, in the FLIP
assay the efficiency of IP is measured directly after IP,
circumventing the need to run time-consuming and
low-throughput gel electrophoresis and immunoblots
(Fig. 1). This is made possible by expressing the target
protein fused to a fluorochrome, for instance YFP (yellow
fluorescent protein) as used here, but other fluorochromes
can be chosen. To this end we developed a Gateway-
compatible [18] human expression vector (HuEV-A) that
adds a N-terminus tag to the protein of interest when the
coding sequence is cloned into the HuEV-A vector. The
tag encodes 3XFLAG, V5 and YFP (yellow fluorescence
protein, Venus) [19] as tags. The coding DNA of interest
can be easily cloned into the HuEV-A vector through the
quick and highly efficient Gateway cloning system (Life
Technologies, Prod. No 11791). The length of the tag
added to the target protein can be shrunk as desired with
FLIP or CRE recombinases to express an untagged pro-
tein, a 3XFLAG-V5 tagged protein or a 3XFLAG, V5 and
YFP-tagged protein (Fig. 2a). In principle, any other vector
enabling the tagging of a target protein of interest to a
fluorochrome at either the N- or C-terminus, or even
tagged internally, may be used.
We have performed IP/IB analysis with hundreds of
antibodies to identify those that are IP-grade. To facili-
tate this screening we cloned hundreds of protein coding
regions into the HuEV-A vector. Proteins expressed as
3XFLAG, V5 and YFP fusion proteins consistently ap-
pear as double bands after SDS-PAGE and immunoblot-
ting (Figs. 2b, 3, 4 and Additional file 1: Figure S4). The
two bands migrate about ~10 kDa apart and are there-
fore more easily observable/sizable for smaller proteins.
The two bands are derived from some unknown prop-
erty of the overexpressed YFP. We performed mass
spectrometry analysis of the proteins isolated from the
upper and lower bands of two randomly chosen proteins
(HES-1 and URI) expressed from the HuEV-A vector. In
both analyses, the nature and quantity of the observed
peptides from the upper and the lower bands were indis-
tinguishable (Additional file 1: Figure S1 and S2), sug-
gesting that both bands contained full-length proteins
with a complete tag. To narrow down the region of the
tag responsible for the double band we performed CRE-
mediated recombination using HuEV-A vectors express-
ing HES-1, URI and Art-27 proteins. Three “daughter”
expression vectors lacking the YFP in the tag were there-
fore obtained. Expression in HeLa cells of the 3XFLAG,
V5 (8KDa) tagged proteins and the 3xFLAG, V5, YFP
(38KDa) tagged proteins showed that the double band
becomes a single band of expected size when the YFP is
absent (Fig. 2b, even lanes). The two bands are therefore
derived from some unknown property of the overexpressed
YFP such as two alternate folded states. Further investiga-
tion is being conducted to elucidate this phenomenon. For
the purpose of development and characterization of the
FLIP assay, the presence of a double band after IP/WB was
not relevant and therefore we utilized the HuEV-A vector
for all the following analyses.
In the FLIP assay, following cell lysis and incubation of
lysate, beads, and antibody, the bead/immune-complex
mixture is washed and then directly visualized with a
fluorescence microscope or automated microscopy
system. If the YFP-tagged protein of interest has been
successfully immunoprecipitated the beads will be
coated with a fluorescent signal detectable under light
with an appropriate excitation wavelength. On the other
hand, if the IP fails, the beads will not fluoresce and no
signal will be detected by fluorescence microscopy.
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Fig. 1 Comparison between FLIP and conventional IP/IB assay. The arrow connecting the two procedures shows how FLIP does not exclude the
possibility of a subsequent conventional IP/IB analysis using the same starting material
a b
Fig. 2 a Schematic of HuEV-A expression. ColE1 ori = bacterial origin of replication; Amp. = Ampicillin resistance cassette; EBNA-1 = Epstein-Barr
nuclear antigen 1; OriP = origin of plasmid replication; Gateway = Gateway cloning cassette; Tet-CMV prom. = Doxycycline inducible promoter;
FRT = flippase recognition target; FLP = flippase recombinase; LoxP = Lox sequence; Cre = Cre recombinase; TEV = TEV protease cleavage site. Note
that treatment with Cre recombinase or FLP recombinase can produce a “short tag” or untagged derivative of the originally cloned ORF, respectively.
b Immunoblot of cell lysates from HeLa cells expressing and empty HuEV-A vector or HES1, URI, or Art-27 proteins expressed from the HuEV-A
expression vector. A version of the HuEV-A expression vectors not containing YFP in the tag (after Cre treatment of the vector) was also used for each
of the proteins and for the empty vector. The proteins were detected with a FLAG-M2 antibody shown in green. Tubulin (shown in red) was used as
loading control
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y = 0.0063x - 0.1601



















10 151.3 25.4 24.2 1.2 1.1
20 193.3 27.0 25.8 1.1 0.8
50 314.3 26.7 24.9 1.8 1.0
100 485.8 28.3 25.6 2.7 0.4
200 913.8 30.3 25.5 4.9 1.6
400 1561.3 34.8 25.7 9.1 1.6
500 1889.3 38.0 25.3 12.7 2.0































































Fig. 3 Comparison of FLIP and IP/IB sensitivity. a Correlation between amount of YFP used and FLIP signal. Two FLIP measurements from 2
different aliquots of beads were used to calculate the range of variability of the measurement (var.). b Immunoblot analysis of the same samples
used in (a) A FLAG antibody was used as a positive control for IP and Western detection. Tubulin was used as a loading control for the total



































96 wells 790.7 760.5 30.2 54.3
48 wells 957.0 820.5 136.5 6.9
24 wells 982.3 813.8 168.5 41.3
12 wells 1677.0 882.3 794.7 111.6
6 wells 2249.2 861.7 1387.5 219.0



































96w 48w 24w 12w 6w 6cm plateb
Fig. 4 Evaluation of the amount of cells necessary for reliable FLIP. HeLa cells were plated, transfected and lysed in wells of different sizes. Lysates
from each well were used to perform FLIP and IP/IB. a FLIP signal (total mean fluorescence measured by ImageJ) using a FLAG Ab subtracted
from the FLIP signal using control IgG antibodies (background) is reported. Two FLIP measurements from 2 different aliquots of beads were used
to calculate the range of variability of the measurement (var.). b The immunoprecipitated beads not used for FLIP were analyzed by immunoblotting.
LY = input lysate; IgG = control IP using IgG antibodies; FLAG = IP of the tagged protein using anti FLAG antibodies. Tubulin was used as loading control
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Quantification of the fluorescence signal of the beads
against a control signal from a control IP performed
using immunoglobulins from a non-immunized mouse
(IgG) provides a reliable indication of the success of the
IP (Fig. 1).
In contrast to the standard IP/IB analysis, the FLIP
assay is a much faster procedure because it is based on
the direct observation of fluorescent target proteins
coating the beads. Moreover the FLIP assay can be inte-
grated into any IP workflow since FLIP analysis requires
only a small fraction of the bead/immune-complex prod-
uct; the left-over beads can be processed for elution and
follow-up analysis as required (Fig. 1).
FLIP is a Sensitive and Scalable Assay
Next we characterized the sensitivity of the FLIP assay
compared to standard IP/IB procedures. For these analyses
we used proteins overexpressed from the HuEV-A vector
that, despite the still double band visible by immuno-
blotting analysis, is an easy to clone vector that enables
Tet-regulation and high expression in mammalian cells.
To interrogate the efficiency and sensitivity of the FLIP
assay compared to standard IP/IB, a randomly chosen
protein (HES-1) expressed from the HuEV-A vector was
used together with a well-known commercial antibody
against FLAG-tag (Anti-FLAG M2; Biorad). Different
amounts of the HuEV-A expressed protein/cell lysate
were used to perform FLIP and IP/IB in parallel. The
tagged-HES-1 was expressed in previously transfected
Tet-on HeLa cells (see experimental procedures). The
fluorescence of the cell lysate was measured and the
amount of YFP per microliter of solution deduced using
a standard curve of purified YFP (Additional file 1:
Figure S3). Different amounts of cell lysate derived from
cells expressing the tagged protein were used in both
FLIP assays or standard IP/IB using an anti-FLAG com-
mercial antibody (Fig. 3a, b). The FLIP signal calculated
using ImageJ was plotted versus the corresponding
amount of YFP-protein used for the assay (Fig. 3a). We
observed a linear increase of fluorescent signal over
background by FLIP similar to the increase of the Im-
munoblot signal following IP, indicating a very similar
sensitivity between the FLIP assay and the IP/IB assay.
To identify the minimum amount of cells necessary to
obtain a reliable FLIP signal, the lysates from HeLa cells
transfected and cultured in different size plates (96, 48,
24, 12, 6-well plates or 6-cm plates) were used to per-
form FLIP and IP/IB analysis in parallel. Even with min-
imal starting material (0.02×106 cells plated in one well
of a 96-well plate) we observed a low but positive FLIP
signal. For all the utilized conditions, a good correlation
between the FLIP and the IP/IB analyses was observed
(Fig. 4). A reliable FLIP signal consistently above back-
ground signal was obtained from 48-well plates.
Overall these observations show an excellent correl-
ation between standard IP/IB analysis as compared to
FLIP analysis. Therefore, the FLIP assay presents sensi-
tivity comparable to the classical IP/IB analysis while
minimizing assay time and sample handling. These fea-
tures confer to the assay a much higher potential for
high-throughput. These advantages of FLIP make our new
technique a relevant and appealing tool for several molecu-
lar biology applications including the high-throughput
screening of antibodies of unknown performance in
immunoprecipitation.
High-Throughout FLIP Screening for IP Competent Mouse
Antibodies
To directly test the application of FLIP in the high-
throughput identification of IP-grade antibodies we
performed FLIP on 46 different mouse monoclonal anti-
bodies (mAb) produced by CDI Laboratories, targeting 23
different proteins. The antibodies were tested using a
96-well plate IP procedure described in Methods. A
10 μl aliquot of the immunoprecipitated beads (about
1.25 % of the beads used for IP) were collected dur-
ing the last wash and used for FLIP analysis; the rest
of the beads (98.75 %) were used for IP/IB analysis as
depicted in Fig. 1. The efficiency of a specific mAb in
precipitating the target protein expressed in HeLa-M2
cells from a HuEV-A expression vector was quantified
after Immunoblotting (Additional file 1: Figure S5), com-
paring the amount of the target protein in the total lysate
with the amount of immunoprecipitated protein. This cal-
culated index (% of total lysate) was correlated with the
FLIP signal calculated using ImageJ (mean fluorescence of
the beads after IP, with the analyzed mAb subtracted from
the mean fluorescence after IP with control mouse IgG
antibodies). The results of this analysis (Fig. 5) showed a
good correlation between the FLIP analysis and the IP/IB
analysis. The majority of the antibodies positive for FLIP
were also positive for IP/IB analysis (28/34) and most of
the antibodies that failed IP/IB also failed FLIP (9/12).
This equal to a success rate of about 80 % (37/46 Abs, as
shown in Fig. 5). Out of the 46 mAbs tested, 3 (6.5 %)
were FLIP false positives (did not pass IP/IB but had a
positive FLIP, shown in yellow in Fig. 5); unlike the true
positives, 23/28 of which had FLIP signals >1.0, all of the
false positive antibodies had FLIP signals <0.6. Also, 6
antibodies (13 %) were FLIP false negative (negative for
FLIP but positive for IP/IB, shown in red in Fig. 5).
These 6 FLIP false negative antibodies had a % IP
index <2, consistent with Abs with relatively low
affinity for their target proteins.
Overall these observations demonstrate the high-
throughput capability of the FLIP assay applied for the
screening of antibodies able to efficiently immunoprecip-
itate their target protein.
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High-Throughput Mini-FLIP
To improve the throughput capability, we performed
FLIP in 0.2 mL PCR tubes using a total volume of just
100 μl (mini-FLIP). Different amounts of lysates were
tested to identify the minimum amount of YFP-protein
necessary to obtain a reliable FLIP signal. HeLa-M2 cells
transfected with a HES-1-expressing HuEV-A construct
were also used for this analysis. Different amounts of lys-
ate (containing 1.34 ± 0.064 ng YFP per μl as deduced by
YFP fluorescence of the solution) were used to perform
FLIP using a FLAG M2 (Biorad) antibody and a total
volume of 100 μl. Here we show a positive FLIP (signal
obtained from FLAG IP higher than the signal obtained
from IgG control IP, which was considered as back-
ground) using just 6.7 ± 0.3 ng of YFP (5 μl of lysate)
and a signal considerably higher than background using
13.4 ± 0.6 ng of YFP (10 μl of lysate) (Fig. 6). This result
shows that “miniaturization” of the FLIP assay is readily
achieved for high-throughput screening of antibodies.
FLIP can be Used to Screen Unpurified Antibodies
If a quick functional screen could be performed before
purification of antibodies from hybridoma supernatants,
considerable amounts of time, material and money could
be saved in avoiding purification and subsequent testing
of antibodies that fail to perform or perform poorly in
immunoprecipitation. The feasibility of using FLIP with
unpurified antibodies was therefore tested. 10 hybridoma
supernatants produced by CDI Laboratories were used to
perform mini-FLIP and IP/IB (Fig. 7). The hybridomas
were produced from mice immunized with a UPF-1
(target protein) polypeptide (416 a.a.) purified from
an E. coli overexpression plasmid; lysates from HeLa-M2
cells transfected with a HuEV-A-UPF1 vector were used
for IP/IB and FLIP testing. IP/IB analysis revealed two
supernatants (NY1.1.1B6 and NY1.1.2B1) that worked
very efficiently in IP, one supernatant (NY1.1.4A10) with a
reasonable efficiency at recognizing and IPing its target
protein, and three supernatants (NY1.1.2C9, NY1.1.4A9













































% tot. lys. mAb-IgG MEAN
ZNF626 R595.1.2C2 0 0.316
ZNF23 R596.1.2A5 0.22 0
ZNF23 R596.2.2A2 1.16 0.407
CEBPE R536.2.2A9 2.70 0.2995
HMGB1 R225.1.2G1 10.06 19.424
HMGB1 R225.1.6B7 11.01 23.5415
HMGB1 R225.2.4E6 9.01 8.411
HMGB1 R225.2.4F10 8.82 9.961
DVL3 R435.1.2E12 1.52 0.753
DVL3 R435.1.3C1 2.52 1.3165
DVL3 R435.1.1A11 4.65 1.86
DVL3 R435.1.2B5 0.23 0.1935
ZKSCAN3 R355.1.1A7 0.27 0
ZKSCAN3 R355.1.1D9 4.13 2.941
ZKSCAN3 R355.1.2D10 0 0
ZCCHC7 JH43.2.2C2 0 0.519
ZCCHC7 JH43.2.1H5 0 0
DR1 R594.1.1A12 10.29 6.3815
ELF3 R379.1.2F10 0 0.1655
KLF16 R518.2.1E9 0 0
NCOA3 R571.1.1D10 0 0
ZNF639 R270.2.3E8 0 0
FOXO3 R5.2.1G5 0 0
FOXO3 R5.2.1D4 2.018900344 0
FOXO3 R5.2.1B7 0 0
COPS3 R4.2.1.4H2 13.42671435 4.1837
COPS3 R147.1.2D9 35.60644123 5.39878
SMAD4 13.2.1A5 10.65 10.19397
SMAD4 R516.2.1G11 0.615942029 0
SMAD4 R516.1.1G12 1.15 5.88242
SMAD4 R516.1.2B3 0.25 0
SMAD4 R516.2.1D12 5.87 6.26718
OBFC1 R248.3.1B4 37.82161645 28.68044
ID4 R260.2.1A6 11.68876728 33.85803
ID4 R260.2.2D6 15.63336986 32.88019
HMGB1 R225.1.6E1 3.119943366 3.8524
HMGB1 R274.1.1E4 1.671797503 0
HMGB1 R274.1.3A7 0.42572 0.76494
ZNF639 R270.2.1F10 1.029962547 2.55917
ZNF639 R270.2.1E7 16.45867998 25.25355
ZNF639 R270.1.2F1 0 0
ZNF410 R585.2.1D7 11.66666667 28.59906
ZNF410 R585.2.2B7 4.010903427 31.09298
MAX R536.1.1E7 27.43 27.24972
NXN 12.5.4.1F7 19.49530516 12.83467
SMARCE1 R330.1.1C4 0 0
a b
Fig. 5 High-throughput FLIP applied to the screening of IP-grade mAbs. a 46 mAb produced and purified by CDI laboratories were tested by FLIP and
immunoblotting (Additional file 1: Figure S3). The FLIP signal (mAb FLIP subtracted from the control IgG FLIP) and the % of the immunoprecipitated
target protein measured after immunoblotting (% tot. lys.) are reported together with the name of the target proteins and the code specific for each
antibody. Negative FLIP values (for which the FLIP signal of the background IP is greater than the FLIP signal after IP with the considered mAb) are
reported as zero. b The FLIP values calculated using ImageJ and the % tot. lysate index obtained after immunoblotting are plotted and
the R2 of the best fit trend-line is reported. The inset shows the plotted values for mAbs that had a positive FLIP value but did not show
a band for the immunoprecipitated target protein by western analysis (FLIP false positives in yellow), mAbs that were shown not to be IP-competent
by both FLIP and IP/western (in green), and mAbs that did not have a positive FLIP value but showed a band for the immunoprecipitated target
protein by immunoblot analysis (FLIP false negatives in red). In blue are reported all the mAbs that show good accordance between FLIP and
IP/western analysis
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Fig. 6 Mini FLIP. a Decreasing amounts of a YFP-tagged protein (HES-1) expressed in HeLa cells transfected with a HuEV-A construct were used
for FLIP analysis in just 100 ml of total volume (images show one of the two pictures used for the analysis). IgG antibodies were used as for previous
experiments as control, while FLAG antibodies were used to IP the YFP-tagged target protein. b Comparison of the FLIP signal obtained using control
IgG antibodies and FLAG antibodies that specifically IP the target protein shows a FLIP signal higher than background, even when using the lower
amount of YFP-protein (6.7 ng YFP/5 ml of lysate). The values reported in the tables are graphed in the histogram. The linear correlation R2 value
between the amount of YFP used for IP and the FLIP signal is reported
ba
c
Fig. 7 FLIP applied to hybridoma supernatants. 10 hybridoma supernatants produced after immunization with a UPF1 polypeptide were tested
by FLIP and IP/IB. a The results of IP/IB, direct examination of the pictures collected after FLIP and ImageJ analysis of the FLIP results are reported
in the table. b One of the two pictures collected after FLIP is also shown for each of the supernatants, FLAG and IgG IP. c IP/IB analysis of the 10
supernatants tested. Immunoblotting was performed using a FLAG antibody and tubulin was used as loading control
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and NY1.1.2C2) with very weak IP capability, but still pre-
senting signals distinguishable from the background (IgG
IP) (Fig. 7a, % tot. lysate column and 7c). ImageJ analysis
of the fluorescence coating the beads after FLIP (Fig. 7a,
FLIP ImageJ column) failed to reliably predict the
performance of the tested supernatants in IP, and was able
to identify only the highest performing hybridomas
(NY1.1.1B6 and NY1.1.2B1). This was probably due to a
high background fluorescence signal and the noticeable
variation of bead number in the different wells during
FLIP assay. Direct examination of the collected FLIP pic-
tures also clearly showed a positive FLIP for the two best
performing supernatants (NY1.1.1B6 and NY1.1.2B1), as
judged by the clear fluorescent ring on the edges of the
beads (Fig. 7b). Although direct visual evaluation of the
pictures from FLIP was able to easily identify the superna-
tants with higher performance in IP, this approach also
failed to clearly identify the supernatants with low IP per-
formance. We therefore developed software for the more
accurate analysis of FLIP images (Fig. 8). This improved
FLIP analysis was able to almost perfectly predict IP be-
havior of all the supernatants tested (Fig. 8c, d). The only
exception was NY1.1.1D4 that passed FLIP analysis but
did not pass IP/IB evaluation. Correlation of the % of total
lysate index and the improved FLIP signal showed a linear
correlation with R2 = 0.83878, suggesting a good concord-
ance between the IP/IB analysis and FLIP analyzed with
our software (further described below).
This result demonstrated that unpurified antibodies
can be efficiently used for FLIP analysis to predict the IP
performance of the tested immunoglobulins.
Development of Software for Automated Analysis of FLIP
Images
The quantification of the FLIP signals presented in
Figs. 3, 4, 5, 6 and 7 was done using ImageJ by measur-
ing the total mean fluorescence of the acquired images
(see Experimental Procedures). This analysis, although
extremely simple and accessible to any laboratory, does
not account for the number of beads as well as their
area, and is extremely sensitive to possible fluorescent
contaminants that aberrantly increase the measured
FLIP signals. Moreover we observed that in control IPs
using normal mouse IgG certain agarose beads exhibited
high fluorescence. Although high, this background fluor-
escence was easily distinguishable from the fluorescence
caused by specific IP because the background fluores-
cence was always uniformly distributed on the beads,
whereas the IP signal was clearly characterized by a ring
of strong fluorescence around the beads. We therefore
developed software that measures and compares the
fluorescence on the rims of the beads with the fluores-
cence present on the body of the beads. This procedure
was applied to every bead in the picture taken as a single
entity. Quantifying FLIP signals in this way therefore is




Fig. 8 Development of software for the automated and improved analysis of FLIP images. a-b A new method to quantify FLIP signals described
in the text and in “Experimental procedures” was applied to the FLIP analysis presented in Fig. 5 (mini-FLIP). The values reported in the table (a)
are graphed in the scatter plot (b) and the R2 of the best-fit trend line is reported. The range of variability (var.) is calculated from 2 measurements
of the fluorescence of the input lysate used for FLIP (X axis) and from 2 separate measurements of the FLIP signal from the beads (Y axis).
c-d The improved FLIP analysis was applied to the screening presented in Fig. 6. The % of total lysate immunoprecipitation index (% tot. lys)
calculated after IP/IB, and the improved FLIP signal, are reported in the column graph and in the table. The only supernatant (NY1.1.1D4) showing a
discrepancy between IP/IB and FLIP is highlighted in gray
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from non-spherical shapes (likely contaminants and/or
overlapping beads). We applied the improved analysis
method to the FLIP analysis presented in Fig. 6 (mini-
FLIP) and Fig. 7 (FLIP using unpurified antibodies) and
obtained a remarkable improvement in FLIP perform-
ance, especially when used for more challenging applica-
tions such as using unpurified antibodies (Fig. 8). The
linear correlation (R2) between the amount of target
protein used for IP and mini-FLIP signal was slightly
improved using the new analysis (from 0.917 to 0.947)
(Fig. 6c versus b). More importantly, we observed a great
increase in separation between FLIP signal from FLAG
IP or tested antibody IP and background signal (IgG IP)
(respectively, Fig. 6b versus Fig. 8a and Fig. 7 versus
Fig. 8c and d). The quantified FLIP signal from control
IPs was always negative using the new methodology of
analysis, reflecting the fact that the edges of the control
beads were actually darker than the body of the beads
(Fig. 8a).
Moreover, the improved analysis clearly outperformed
the ImageJ analysis in FLIP done using unpurified anti-
bodies (Figs. 7 and 8c, d). Analysis of FLIP results with
the improved method produced FLIP values that almost
perfectly correlated with the IP/IB in our screening of
hybridoma supernatants produced after immunization of
mice with UPF1 protein (Fig. 8c, d and previous
paragraph).
The principles used by the new quantification method
are described in further details in the “experimental
procedures” section. A publicly available analysis tool for
FLIP pictures can be found at http://openslice.fenyolab.
org/flip.
This new tool improves the sensitivity of the FLIP,
especially for the low performing antibodies and moreover
increases the throughput of the FLIP assay, rendering this
method an extremely easy, fast, and reliable way to screen
antibodies or even hybridoma supernatants for applica-
tions in immunoprecipitation.
Discussion
Immunoprecipitation (IP) procedures are applied to a
large variety of molecular biology assays, including pro-
tein purification, concentration, co-immunoprecipitation
and chromatin immunoprecipitation [2–8]. The classical
IP procedure is often coupled to immunoblotting ana-
lysis, a technique suited to low throughput analysis of
only a few samples [10, 20, 21]. Here we describe and
characterize FLIP (Fluorescence IP), which couples con-
ventional IP to the direct observation and/or quanti-
fication of a fluorescently tagged target protein on the
surface of beads. This approach is faster and cheaper
than using IB to measure the success of an IP, and is
thus amenable to high-throughput screens. A major
limitation of the IP assay is often the availability of
antibodies able to efficiently immunoprecipitate the tar-
get protein [22]. Here we applied FLIP to the screening
of mouse monoclonal antibodies in order to quickly
screen and identify those able to immuneprecipitate
their corresponding target protein.
Here we show that FLIP has a similar sensitivity to the
IP/IB assay and that FLIP can also be miniaturized to in-
crease throughput by minimizing both volume of cell
lysate and amount of antibody used for IP. Another
advantage of FLIP is the use of fluorescently labeled
target protein, which ensures a degree of specificity for
the antibodies that pass FLIP. Indeed, given that the
target protein is the only fluorescently tagged protein in
the cell lysate used for IP, the presence of fluorescence
coating the agarose beads after immunoprecipitation
indicates selective binding of the tested antibody to the
target protein. On the other hand, the FLIP assay is
“blind” to any possible non-specific binding of the tested
antibody to proteins different from the fluorescently
labeled target protein. Another possible limitation of
FLIP is that it does not currently give any information
about the ability of the tested antibody to recognize the
target protein in its denatured state and therefore FLIP
cannot predict the behavior of antibodies in immuno-
blotting assays. To this end, FLIP could theoretically be
used using protein solutions/lysates pre-treated with de-
naturing conditions such as high SDS concentrations
and/or reducing agents [5]. This approach may be
possible and somehow informative because of the high
stability of GFP and GFP derived fluorophores that can
withstand denaturing conditions undergoing partial de-
naturation and still remaining fluorescent [23].
Also, FLIP cannot assay the performance of an anti-
body in IP of endogenous proteins because it relies on
the overexpression of the target protein. Nevertheless,
we show here that FLIP can easily be integrated into
classical IP/IB procedures with no disruption and no
diminished sensitivity of the latter. This allows for fur-
ther characterization of the antibodies after FLIP screen-
ing for the IB analysis of bands of the endogenous
protein. Moreover, FLIP relies on the overexpression of
the target protein as a fluorophore-tagged fusion and
therefore requires the cloning of the gene of interest into
a suitable expression vector. To this end we developed a
flexible mammalian expression vector named HuEV-A
that combines the simplicity of Gateway cloning with
the flexibility of our 3xFLAG-V5-YFP tag [18, 19, 24].
We used the Life Technologies Ultimate ORF collection,
compatible with Gateway cloning (Gateway entry clone
format) to construct a HuEV-A library of proteins. Also,
the HuEV-A tag can be dramatically reduced in size
with simple Cre recombination to a 3xFLAG-V5 tag,
or the entire tag can be eliminated by employing
FLP recombination.
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The FLIP assay is very similar in basic concept to the pre-
viously described LUMIER (luminescence-based mamma-
lian interactome mapping) assay [12, 13] which has been
applied to a wide range of applications, including identifica-
tion of new protein-protein interactions [12, 25–27], valid-
ation of yeast two hybrid screening hits [28, 29] and
identification of particular antibodies in patients’ blood
(Luciferase Immunoprecipitation Systems or LIP) [30].
LUMIER exploits the overexpression of a target protein
fused to Renilla luciferase and utilizes quantification of lu-
minescence signal after immunoprecipitation. As for FLIP,
the success of the immunoprecipitation of the target fu-
sion protein can be efficiently and easily determined by
high-throughput measurements: measurement of lumi-
nescence after incubation with a luciferase substrate in the
case of LUMIER and LIP, and measurement of the fluores-
cence coating the immunoprecipitated beads in the case
of FLIP. Despite the great success and the many applica-
tions of the LUMIER system no alternative assays with
high-throughput capability has been developed for IP
analysis until now.
Our FLIP assay is not meant to substitute for the
LUMIER assay, which is probably more sensitive com-
pared to IP/WB and FLIP analysis itself. Our FLIP assay
is meant to complement the previously known tech-
niques (IP/WB and LUMIER assays) in high-throughput
procedures challenging for luciferase reactions or in
contexts in which microscopy observations are more
amenable than luciferase signal quantification or in
which fluorophore tagging is preferable to Renilla tag-
ging. The FLIP assay is an additional tool for the fast
screening of IP reactions. FLIP can also be envisioned as
an orthogonal assay to the LUMIER system because
“preys” tagged with FLAG and a fluorophore of choice
can be used with Renilla tagged “baits” (see [12]) to verify
and quantify efficiency of IP before luminescence quantifi-
cation. In this context our HuEV-A expression vector that
includes a FLAG, V5 and YFP tag would be optimal.
Compared to IP-Western blotting, some information
such as the nonspecific reactivity of the antibody to-
wards non-target proteins, and/or the preferential re-
activity towards specific isoforms or splice variants of
the target protein, are lost. Nevertheless, we foresee an
extremely useful application of FLIP in screening for
antibodies that function efficiently in IP assays. For in-
stance, many unpurified antibodies can be tested by
FLIP directly using hybridoma supernatants. After selec-
tion of the FLIP-positive clones, a reduced number of
the antibodies would need to be purified and character-
ized further by IP/IB or other assays. Moreover, because
of the minimal material used in the FLIP analysis, a new
IP does not need to be performed again for the FLIP-
positive antibodies, as the left-over beads from FLIP ana-
lysis can be used for the follow-up characterizations.
Here we show that FLIP is a fast and reliable method
that can partially substitute and easily complement the
conventional IP/IB procedure. This new technique can
be directly applicable to the high-throughput screening
for the identification of IP-grade antibodies.
Conclusions
Immunoprecipitation (IP) is a powerful and informative
procedure often coupled to immuno-blotting analysis
(IP/IB). IP/IB has limited scalability to high-throughput
pipelines. Here we describe a novel, fast and easily scal-
able method called FLIP (FLuorescence IP) that can par-
tially substitute and complement the conventional IP/IB
procedure. Beside the description and application of the
new method, we also built and characterized a flexible
plasmid (HuEV-A) for YFP protein tagging and we
developed a publicly available analysis tool for FLIP
pictures that improves the sensitivity of FLIP.
Additional file
Additional file 1: Figure S1. Mass spectrometry of tryptic peptides of
YFP fusion proteins recovered from upper and lower bands of HES-1
expressed the HuEV-A vector. Figure S2. Mass spectrometry of tryptic
peptides of YFP fusion proteins recovered from upper and lower bands
of URI as in Figure S1. Figure S3. Standard curve of YFP amounts versus
fluorescence reading (excitation 475 nm, emission 527 nm). Figure S4. a)
HeLa cells were plated and transfected with Fugene-HD (Promega) in
different size wells according with the parameters reported in the table.
b) After lysis of the cells in each of the wells, the YFP fluorescence of
10 ml of solution used for IP was 2 measured. Figure S5. Tet-ON HeLa
cells were transfected with the HuEV-A construct encoding the target
protein with an N-terminal FLAG, YFP (Venus) and V5 tag under a
tet-inducible promoter. (PDF 5435 kb)
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